Vertex Pharma (VRTX) Tops Q1 EPS by 72c, Revenues Beat; Raises FY20 Revenues Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. ON
6. CRWD
7. INSP
8. HNGE
9. MRVL
10. MTCH

Go back to Vertex Pharma (VRTX) Tops Q1 EPS by 72c, Revenues Beat; Raises FY20 Revenues Guidance

Vertex Reports First-Quarter 2020 Financial Results

April 29, 2020 4:01 PM EDT

-Product revenues of $1.52 billion, a 77% increase compared to Q1 2019-

-Company raises revenue guidance; now expects 2020 CF revenues of $5.3 to $5.6 billion-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2020 and revised upward its full-year 2020 financial guidance for total cystic fibrosis (CF) product revenues.

"The COVID-19 pandemic has presented unprecedented challenges to societies, communities and businesses around the world, and while these global challenges will continue... More